Molecular structure of LY 2087101, CAS Number: 913186-74-0
LY 2087101 (CAS 913186-74-0)
Application:
LY 2087101 is an allosteric potentiator of α7, α4β2 and α4β4 nAChRs
CAS Number:
913186-74-0
Purity:
>98%
Molecular Weight:
318.39
Molecular Formula:
C15H11FN2OS2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY 2087101 is an allosteric potentiator of α7, α4β2 and α4β4 nAChRs with selectivity against α3β4 nAChRs.
LY 2087101 (CAS 913186-74-0) References
- Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. | Faghih, R., et al. 2007. Recent Pat CNS Drug Discov. 2: 99-106. PMID: 18221220
- Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. | Young, GT., et al. 2008. Proc Natl Acad Sci U S A. 105: 14686-91. PMID: 18791069
- Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. | Taly, A., et al. 2009. Nat Rev Drug Discov. 8: 733-50. PMID: 19721446
- Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. | Hajós, M. and Rogers, BN. 2010. Curr Pharm Des. 16: 538-54. PMID: 19909231
- Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator. | Collins, T. and Millar, NS. 2010. Mol Pharmacol. 78: 198-204. PMID: 20463059
- In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening. | Dey, R. and Chen, L. 2011. J Biomol Struct Dyn. 28: 695-715. PMID: 21294583
- Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. | Gill, JK., et al. 2011. Proc Natl Acad Sci U S A. 108: 5867-72. PMID: 21436053
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. | Williams, DK., et al. 2011. Biochem Pharmacol. 82: 915-30. PMID: 21575610
- Structure and pharmacology of pentameric receptor channels: from bacteria to brain. | Corringer, PJ., et al. 2012. Structure. 20: 941-56. PMID: 22681900
- Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status. | Vallés, AS., et al. 2014. CNS Drugs. 28: 975-87. PMID: 25248971
- Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. | Grupe, M., et al. 2015. Basic Clin Pharmacol Toxicol. 116: 187-200. PMID: 25441336
- Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. | Terry, AV., et al. 2015. Biochem Pharmacol. 97: 388-398. PMID: 26231940
- Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice. | Moerke, MJ., et al. 2016. Eur J Pharmacol. 786: 169-178. PMID: 27238974
- NS6740, an α7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity. | Papke, RL., et al. 2018. Neurosci Lett. 677: 6-13. PMID: 29679680
- Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators. | Wilkerson, JL., et al. 2020. Neuropharmacology. 168: 108008. PMID: 32113032
Activator of:
AChR α 3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY 2087101, 10 mg | sc-361235 | 10 mg | $159.00 | |||
| US: Only available in the US | ||||||
LY 2087101, 50 mg | sc-361235A | 50 mg | $645.00 | |||
| US: Only available in the US | ||||||